Current Progress in Treating Systemic Lupus Erythematosus Using Exosomes/MicroRNAs.

Abstract

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease associated with impaired organ functions that can seriously affect the daily life of patients. Recent SLE therapies frequently elicit adverse reactions and side effects in patients, and clinical heterogeneity is considerable. Mesenchymal stromal cells (MSCs) have anti-inflammatory, tissue repair, and immunomodulatory properties. Their ability to treat autoimmune diseases largely depends on secreted extracellular vesicles, especially exosomes. The effects of exosomes and microRNAs (miRNAs) on SLE have recently attracted interest. This review summarizes the applications of MSCs derived from bone marrow, adipocyte tissue, umbilical cord, synovial membrane, and gingival tissue, as well as exosomes to treating SLE and the key roles of miRNAs. The efficacy of MSCs infusion in SLE patients with impaired autologous MSCs are reviewed, and the potential of exosomes and their contents as drug delivery vectors for treating SLE and other autoimmune diseases in the future are briefly described.

• Authors: Yi-Jing Liu, Hai-Bing Miao, Shu Lin, Zhen Chen
• Journal: Cell transplantation (Cell Transplant) 2023 Jan-Dec Vol. 32 Pg. 9636897221148775 ISSN: 1555-3892 [Electronic] United States
• PMID: 36661068 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)

Chemical References

• MicroRNAs

Topics

• Humans
• Autoimmune Diseases (genetics, immunology, therapy)
• Exosomes (genetics, immunology)
• Extracellular Vesicles (genetics, immunology)
• Lupus Erythematosus, Systemic (genetics, immunology, therapy)
• MicroRNAs (genetics, immunology)
• Mesenchymal Stem Cells (immunology)